SCHEMBL8263192

SCHEMBL8263192

COC1CN(c2ccc3c(c2)CNC3)C1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
IDH1 O75874 2/20 0.35
ASIC3 Q9UHC3 1/20 0.35
EGLN2 Q96KS0 1/20 0.33
HTR6 P50406 2/20 0.33
HTR2C P28335 1/20 0.33
SLC6A4 P31645 1/20 0.33
RXRA P19793 2/20 0.31
GRIN1 Q05586 2/20 0.31
GRIN2B Q13224 2/20 0.31
HTR1A P08908 1/20 0.31
HTR1D P28221 1/20 0.31
HTR1B P28222 1/20 0.31
ADRB1 P08588 1/20 0.31
DDB1 Q16531 1/20 0.31
CRBN Q96SW2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21326131 0.88 HTR6 (0.45) ASIC3HTR6
Trifluoroacetic Acid SCHEMBL3873744 0.87 IDH1 (0.36) CYP1A2CYP2D6IDH1
Hydrochloric Acid SCHEMBL29587340 0.87 HTR6 (0.44) ASIC3HTR6
Hydrochloric Acid SCHEMBL21326141 0.87 HTR6 (0.44) ASIC3HTR6
SCHEMBL8261639 0.84 ASIC3 (0.39) CYP1A2CYP2D6IDH1ASIC3HTR6
Hydrochloric Acid SCHEMBL3873695 0.83 ASIC3 (0.38) CYP1A2CYP2D6IDH1ASIC3HTR6
SCHEMBL38653303 0.78 CYP1A2 (0.39) CYP1A2CYP2D6ASIC3HTR6HTR2C
SCHEMBL370808 0.73 ASIC3 (0.59) ASIC3
SCHEMBL38652796 0.72 ASIC3 (0.43) CYP1A2CYP2D6ASIC3HTR6HTR2C
SCHEMBL3878501 0.72 ACHE (0.45) ASIC3HTR2CADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188139-B2 Heterocyclic-substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
US-8188139-B2 Heterocyclic-substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
EP-1848694-B1 HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 HOFFMANN LA ROCHE (CH) 2009-11-25 EP disclosed
US-20090203665-A1 HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES JOLIDON SYNESE 2009-08-13 US disclosed
US-20090203665-A1 HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES JOLIDON SYNESE 2009-08-13 US disclosed
US-7557114-B2 Heterocyclic-substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2009-07-07 US disclosed
US-7557114-B2 Heterocyclic-substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2009-07-07 US disclosed
WO-2006082001-A1 HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 F.HOFFMANN-LA ROCHE AG (CH) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203665-A1 HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES CYP2B6, CYP2D6, CYP1A2 CYP1A2 3/4885CYP2D6 2/4885IDH1 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.